Pharmaceutical factors affecting the effectiveness of levothyroxine therapy

Hypothyroidism is one of the most common endocrine diseases that requires lifelong replacement therapy with levothyroxine. However, the effectiveness of treatment depends not only on the correct dosage, but also on the stability of the drug, the bioavailability of the active substance and the effect of excipients. To improve the stability of levothyroxine, L-Thyroxine Berlin-Chemie was developed with an updated composition of excipients. Thanks to the improved formulation, the drug does not contain any excipients that require special labeling, as well as substances of animal origin, which reduces the risk of adverse reactions and makes it suitable for patients with dietary restrictions. Aluminum foil blister packaging prevents exposure to moisture, light and oxygen, maintaining the stability of the active substance throughout the shelf life. Snap-tab technology allows easy division of tablets without fragmentation, ensuring accurate dosing. An important advantage of the new formulation is the ability to store the drug at temperatures up to 30°C without loss of efficacy, which makes it convenient for use in various climatic conditions. This is especially important, since the stability of levothyroxine plays a key role in maintaining therapeutic control and preventing fluctuations in hormone levels in the blood. Thus, the new formulation of L-Thyroxin Berlin-Chemie provides high stability, safety and better tolerability for different categories of patients with hypothyroidism.

References

1. Taylor P.N., Albrecht D., Scholz A. et al. (2018) Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol., 14(5): 301–316.
2. Zamwar U.M., Muneshwar K.N. (2023) Epidemiology, Types, Causes, Clinical Presentation, Diagnosis, and Treatment of Hypothyroidism. Cureus, 15(9): e46241.
3. Asvold B.O., Vatten L.J., Bjøro T. (2013) Changes in the prevalence of hypothyroidism: the HUNT Study in Norway. Eur. J. Endocrinol., 169: 613–620. doi: 10.1530/EJE-13-0459.
4. Garmendia Madariaga A., Santos Palacios S., Guillén-Grima F. et al. (2014) The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab., 99: 923–931. doi: 10.1210/jc.2013-2409.
5. Bridwell R.E., Willis G.C., Gottlieb M. et al. (2021) Decompensated hypothyroidism: A review for the emergency clinician. Am. J. Emerg. Med., 39: 207–212.
6. Díez J.J., Iglesias P. (2023) Prevalence of thyroid dysfunction and its relationship to income level and employment status: a nationwide population-based study in Spain. Hormones, 22(2): 243–252. doi: 10.1007/s42000-023-00435-9.
7. Okosieme O., Gilbert J., Abraham P. et al. (2016) Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. Clin. Endocrinol. (Oxf.), 84(6): 799–808. doi: 10.1111/cen.12824.
8. Wartofsky L. (2002) Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin. Pharmacother., 3(6): 727–732.
9. Caron P., Grunenwald S., Persani L. et al. (2022) Factors influencing the levothyroxine dose in the hormone replacement therapy of primary hypothyroidism in adults. Rev. Endocr. Metab. Disord., 23(3): 463–483. doi: 10.1007/s11154-021-09691-9.
10. Patel H., Stalcup A., Dansereau R. et al. (2003) The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int. J. Pharm, 264(1–2): 35–43.
11. Collier J.W., Shah R.B., Gupta A. et al. (2010) Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate. AAPS PharmSciTech, 11: 818–825. doi: 10.1208/s12249-010-9434-8.
12. Kaur N., Suryanarayanan R. (2021) Levothyroxine sodium pentahydrate tablets–formulation considerations. J. Pharm. Sci., 110(12): 3743–3756.
13. Hamad M.L., Engen W., Morris K.R. (2015) Impact of hydration state and molecular oxygen on the chemical stability of levothyroxine sodium. Pharmaceutical development and technology, 20(3): 314–319. doi: 10.3109/10837450.2013.862635.
14. Shah H.S., Chaturvedi K., Hamad M. et al. (2019) New insights on solid-state changes in the levothyroxine sodium pentahydrate during dehydration and its relationship to chemical instability. AAPS PharmSciTech, 20: 1–10.
15. Robertson S.G., Glass B.D. (2019) Repackaging levothyroxine sodium tablets: storage conditions to maintain stability in a hot and humid environment. J. Pharm. Pract. Res., 49(5): 414–420. doi: 10.1002/jppr.1528.
16. Won C.M. (1992) Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharmaceutical research, 9: 131–137.
17. Garber J.R., Cobin R.H., Gharib H. et al. (2012) American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract., 18(6): 988–1028. doi: 10.4158/EP12280.
18. Benvenga S., Papi G., Antonelli A. (2017) Refractory Hypothyroidism Due to Improper Storage of Levothyroxine Tablets. Front. Endocrinol. (Lausanne), 8: 155.
19. Mohamed I., Abdallah S. (2016) Stability of levothyroxine sodium tablets marketed in Sudan. J. Pharm. Biomed. Sci., 6(05): 328–332.
20. Chun J. (2022) Stability of levothyroxine tablets in blister packaging versus bottles and vials under simulated in-use conditions. AAPS Open, 8(1): 15.
21. Shah R.B., Collier J.S., Sayeed V.A. et al. (2010) Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech, 11(3): 1359–1367. doi: 10.1208/s12249-010-9515-8.
22. Obinna E., Martin M., Syed Ali I. et al. (2021) Levothyroxine Sodium — An Overview of Challenges Related to Interchangeability and Stability of Different Formulations. J. Endocrinol. Thyroid Res., 6(1): 555679.
23. patents.google.com/patent/EP3576795A1/en.
24. patents.google.com/patent/EP1408948A2/en.
25. http://www.ema.europa.eu/en/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use.
26. zakon.rada.gov.ua/laws/show/z1069-05#Text.
27. Concordet D., Gandia P., Montastruc J.L. et al. (2019) Levothyrox® new and old formulations: are they switchable for millions of patients? Clin. Pharmacokinet., 58(7): 827–833.
28. Hegde V.L., Venkatesh Y.P. (2004) Anaphylaxis to excipient mannitol: evidence for an immunoglobulin E-mediated mechanism. Clin. Exp. Allergy, 34(10): 1602–1609. doi: 10.1111/j.1365-2222.2004.02079.x.
29. Venturini Díaz M., Vidal Oribe I., D’Elia Torrence D. et al. (2022) New Challenges in Drug Allergy: the Resurgence of Excipients. Curr. Treat Options Allergy, 9(3): 273–291. doi: 10.1007/s40521-022-00313-6.
30. Caballero M.L., Krantz M.S., Quirce S. et al. (2021) Hidden Dangers: Recognizing Excipients as Potential Causes of Drug and Vaccine Hypersensitivity Reactions. J. Allergy Clin. Immunol. Pract., 9(8): 2968–2982. doi: 10.1016/j.jaip.2021.03.002.
31. Robertson G.L. (2006) Food packaging: principles and practice. CRC press, 550 р.
32. Allinson J.G., Dansereau R.J., Sakr A. (2001) The effects of packaging on the stability of a moisture sensitive compound. Int. J. Pharm., 221(1–2): 49–56.
33. cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/regulatory-standards/trs902-annex9.pdf?sfvrsn=82b4c57d_2.
34. compendium.com.ua/dec/273294/.